Article

Exchange Maps Out Plan for Next Year

The state Health Benefit Exchange board finalized and submitted its request to federal officials for a $196 million Level 1.2 establishment grant -- essentially mapping out the exchange's plans over the next year.

Exchange executive director Peter Lee made the announcement at the board's July 19 meeting in Oakland.

Read the full story: http://tinyurl.com/d4po8zl

Source: California Healthline

Related Videos
Dr Kimlin Tam Ashing
1 expert in this video
1 expert in this video
Dr John Heymach
John Michael O'Brien, PharmD, MPH
Julia Logan
Dr John Heymach
4 experts are featured in this series.
Related Content
senior scientist | Image credit: Ohio State University
April 28th 2025

Proving the Concept: A Sampler of Early Stage Science at AACR 2025

Mary Caffrey
From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ground.
managed care cast logo
April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD
On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Because serum analysis is already used to diagnose RA, track its progression, and understand response to therapy, the authors investigated whether reliable biomarkers could be found for refractory RA. | Image credit: angellodeco - stok.adobe.com
April 28th 2025

Serum Biomarkers for Refractory Active Rheumatoid Arthritis Remain Elusive

Jared Kaltwasser
New research suggests classical biomarkers cannot discriminate between refractory and non-refractory rheumatoid arthritis.
Managed Care Cast Thumbnail
April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Triple combination therapy guided by MRD showed promise in R/R CLL. | Image credit: Matthieu - stock.adobe.com
April 28th 2025

MRD-Guided Triplet Therapy Leads to Deep Remissions in R/R CLL

Jared Kaltwasser
Minimal residual disease (MRD)-guided triple therapy showed promising results for relapsed chronic lymphocytic leukemia (CLL), achieving high rates of undetectable disease and prolonged survival.
AACR Panelists Call on Scientists to Stand Up Against Cuts That Threaten Progress, Patients, and Future Discoveries
April 27th 2025

AACR Panelists Call on Scientists to Stand Up Against Cuts That Threaten Progress, Patients, and Future Discoveries

Mary Caffrey
The session follows the American Association for Cancer Research's (AACR) prior call to action against executive orders that would harm the National Institutes of Health.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo